Glaukos (GKOS) Stock Overview
An ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GKOS from our risk checks.
GKOS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Glaukos Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$97.79 |
| 52 Week High | US$130.23 |
| 52 Week Low | US$73.16 |
| Beta | 0.74 |
| 1 Month Change | -13.48% |
| 3 Month Change | -10.19% |
| 1 Year Change | 1.23% |
| 3 Year Change | 97.92% |
| 5 Year Change | 13.79% |
| Change since IPO | 213.23% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With Glaukos Corporation's (NYSE:GKOS) Prospects As Shares Rocket 25%
Nov 21
Here's Why We're Not At All Concerned With Glaukos' (NYSE:GKOS) Cash Burn Situation
Sep 19Glaukos' Pipeline And High Valuation: A Risky Hold With Long-Term Upside
Sep 12Why We're Not Concerned About Glaukos Corporation's (NYSE:GKOS) Share Price
Jun 16Companies Like Glaukos (NYSE:GKOS) Can Afford To Invest In Growth
Apr 22
Launch Of iDose TR And Epioxa Will Transform Eye Treatments By 2025
Anticipated launches of iDose TR and Epioxa could significantly boost revenue and strengthen market position in glaucoma and corneal health sectors.Glaukos: Still Bullish, But Embedded Expectations Are Now High
Dec 21Glaukos Corporation: Ripe For Some Consolidation
Sep 11Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun
May 30Shareholder Returns
| GKOS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -12.8% | -5.4% | -2.3% |
| 1Y | 1.2% | -8.5% | 20.4% |
Return vs Industry: GKOS exceeded the US Medical Equipment industry which returned -7.6% over the past year.
Return vs Market: GKOS underperformed the US Market which returned 21.2% over the past year.
Price Volatility
| GKOS volatility | |
|---|---|
| GKOS Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GKOS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GKOS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,094 | Tom Burns | www.glaukos.com |
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Glaukos Corporation Fundamentals Summary
| GKOS fundamental statistics | |
|---|---|
| Market cap | US$5.97b |
| Earnings (TTM) | -US$187.69m |
| Revenue (TTM) | US$507.44m |
Is GKOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GKOS income statement (TTM) | |
|---|---|
| Revenue | US$507.44m |
| Cost of Revenue | US$111.81m |
| Gross Profit | US$395.63m |
| Other Expenses | US$583.32m |
| Earnings | -US$187.69m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.23 |
| Gross Margin | 77.97% |
| Net Profit Margin | -36.99% |
| Debt/Equity Ratio | 0% |
How did GKOS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 11:49 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Glaukos Corporation is covered by 26 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ravi Misra | Berenberg |
| Joanne Wuensch | BMO Capital Markets Equity Research |
| Robert Hopkins | BofA Global Research |